Law tracker
MDMA: the law in the United States
What federal law says about mdma, and what individual states have done, from the statutes, bills and official pages cited on each line. Checked 26 Oct 2026. Not legal advice.
Federal law
- MDMA (3,4-methylenedioxymethamphetamine) is a Schedule I controlled substance (21 CFR 1308.11). (eCFR (Office of the Federal Register), current)
States that have acted
Connecticut
- Connecticut runs a psychedelic-assisted therapy pilot program in the Department of Mental Health and Addiction Services, administered by a medical school (currently Yale University), in which participants receive MDMA- or psilocybin-assisted therapy as part of an FDA-approved research program. (Connecticut Office of Legislative Research, 2026)
North Carolina
- SB 1018, the HEAL Act, filed 30 April 2026, would create a Breakthrough Therapies Research Grant Fund in DHHS for two competitive grants for in-state research on psychedelic drugs including ibogaine, MDMA and psilocybin for veterans, first responders and frontline health workers. (North Carolina General Assembly, 4 May 2026)
Utah
- Under Utah Code 58-37-309, a qualifying healthcare system may develop a behavioral health treatment program using a form of psilocybin or MDMA that is in FDA Phase 3 testing, if the system determines the treatment is supported by a broad collection of scientific and medical research. (Utah State Legislature, 6 May 2026)
State bills that name mdma
| State | Bill | What it would do | Status |
|---|---|---|---|
| Arizona | SB 15422026 (57th Legislature, 2nd Regular) | controlled substances; approval; use; researchWould have appropriated $10 million for MDMA (midomafetamine) PTSD research and conformed scheduling for FDA-approved drugs. | Held in committee; not enacted (Arizona State Legislature, 2026; Arizona State Legislature, 28 Jan 2026) |
| Connecticut | SB 1912026 | An Act Concerning the Psychedelic-Assisted Therapy Pilot ProgramExpands eligibility for the DMHAS psilocybin and MDMA therapy pilot to residents 18 and older and removes its automatic end on DEA approval. | Signed 4 June 2026 (Public Act 26-108), effective 1 July 2026 (Connecticut General Assembly, 4 Jun 2026; Connecticut Office of Legislative Research, 2026) |
| Texas | HB 401489th Legislature (2025) | Relating to a study on the use of psychedelic therapies in the treatment of certain conditionsWould have had the Health and Human Services Commission, with Baylor College of Medicine and Dell Medical School, study MDMA, psilocybin and ketamine therapies for PTSD, depression and co-occurring conditions. | Passed the House; referred to Senate Health & Human Services on 19 May 2025 and died when the regular session ended (Texas Legislature Online, 19 May 2025; Texas Legislature Online, 2025) |
| Utah | S.B. 2482025 General Session | Controlled Substances AmendmentsWould have amended the psilocybin and MDMA treatment provisions, provided for automatic rescheduling of a certain type of psilocybin if rescheduled federally, and extended a repeal date. | Enacting clause struck and filed in the Senate (died) (Utah State Legislature, 7 Mar 2025) |